8-K: Relay Therapeutics Outlines 2025 Priorities, Highlighting RLY-2608 Progress and Pipeline Expansion

Relay Therapeutics is advancing its pipeline with a focus on RLY-2608 in breast cancer and expanding into vascular malformations, Fabry disease, and NRAS-driven solid tumors, supported by a strong cash position.

Summary

• Relay Therapeutics presented at the J.P. Morgan Healthcare Conference, outlining their 2025 priorities and pipeline progress.
• The company is focused on advancing RLY-2608, a mutant-selective PI3K inhibitor, with a planned pivotal trial start in 2025 for post-CDK4/6 breast cancer patients.
• Interim data for RLY-2608 in combination with fulvestrant shows a median progression-free survival (mPFS) of 11.4 months in 2L+ patients and 9.2 months in 2L only patients.
• Relay Therapeutics is also expanding its pipeline to include clinical starts for RLY-2608 in vascular malformations, a non-inhibitory chaperone for Fabry disease, and an NRAS-selective inhibitor for solid tumors, all expected in 2025.
• The company reported approximately $840 million in cash as of the end of Q3 2024.
• Relay Therapeutics is targeting large markets with significant unmet needs, including breast cancer, vascular malformations, Fabry disease, and NRAS-driven solid tumors.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data for RLY-2608, a robust cash position, and expansion into new therapeutic areas. The company is clearly executing on its strategy and has a clear path forward.

Positives

• RLY-2608 shows promising efficacy data with a 11.4 month median PFS in 2L+ breast cancer patients.
• The company has a strong cash position of approximately $840 million.
• Relay Therapeutics is expanding its pipeline into multiple new therapeutic areas with significant market potential.
• The company's Dynamo platform is creating mutant-selective molecules, addressing limitations of non-selective inhibitors.
• The planned pivotal trial for RLY-2608 is a significant step towards potential commercialization.

Negatives

• The document notes that cross-trial comparisons cannot be made due to differences in trial design and patient populations.
• The document highlights the limitations of current non-selective PI3K inhibitors, suggesting a need for better options.
• The document mentions that current therapies for vascular malformations have incomplete responses and side effects.
• The document notes that current therapies for Fabry disease have limitations in Gal activation and mutational coverage.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• Clinical trial results may not be predictive of future outcomes.
• The company's ability to obtain regulatory approvals is not guaranteed.
• There are risks associated with the competitive landscape and market opportunities.
• The company's ability to manufacture product candidates in conformity with FDA requirements is a risk.

Future Outlook

Relay Therapeutics anticipates several key milestones in 2025, including the start of a pivotal trial for RLY-2608 in breast cancer, clinical trial initiations in vascular malformations, Fabry disease, and NRAS-driven solid tumors, and the progression of four unnamed research programs. The company also expects to continue to leverage its Dynamo platform to identify new product candidates.

Industry Context

Relay Therapeutics is operating in a competitive landscape with other companies developing PI3K inhibitors and therapies for breast cancer, vascular malformations, Fabry disease, and NRAS-driven solid tumors. The company's focus on mutant-selective inhibitors and novel approaches positions them to potentially address unmet needs in these areas. The document highlights the limitations of current non-selective PI3K inhibitors, suggesting a need for better options, which Relay aims to provide.

Comparison to Industry Standards

• The document compares RLY-2608's efficacy to existing treatments like alpelisib, capivasertib, and inavolisib in breast cancer, noting RLY-2608's 11.4 month mPFS in 2L+ patients.
• The document references the CAPItello-291 trial for capivasertib, highlighting a 5.5 month mPFS in a similar patient population, suggesting RLY-2608 may offer an improvement.
• The document also mentions Vijoice (alpelisib) as an approved therapy for vascular malformations, indicating a competitive landscape for RLY-2608 in this area.
• The document notes that current Fabry disease therapies have limitations, suggesting a potential advantage for Relay's non-inhibitory chaperone approach.
• The document compares the efficacy of pan-RAF/RAS and MEK inhibitors in NRAS-driven solid tumors, highlighting the limited efficacy and tolerability of these agents, suggesting a potential advantage for Relay's NRAS-selective inhibitor.

Stakeholder Impact

• Shareholders may benefit from the potential commercial success of RLY-2608 and other pipeline candidates.
• Patients with breast cancer, vascular malformations, Fabry disease, and NRAS-driven solid tumors may benefit from new treatment options.
• Employees may benefit from the company's growth and success.
• The company's success may impact suppliers and collaborators.

Next Steps

• Initiate a pivotal trial for RLY-2608 in post-CDK4/6 breast cancer patients in 2025.
• Start clinical trials for RLY-2608 in vascular malformations in Q1 2025.
• Start clinical trials for the Fabry disease chaperone and the NRAS-selective inhibitor in the second half of 2025.
• Progress four unnamed research programs.

Key Dates

Keywords

RLY-2608, PI3K inhibitor, breast cancer, vascular malformations, Fabry disease, NRAS inhibitor, clinical trials, pivotal trial, Dynamo platform, mutant-selective, targeted therapy